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Innate immunityViruses have developed a battery of distinct strategies to overcome the very sophisticated defense
mechanisms of the infected host. Throughout the process of pathogen–host co-evolution, viruses have
therefore acquired the capability to prevent host cell apoptosis because elimination of infected cells via
apoptosis is one of the most ancestral defense mechanism against infection. Conversely, induction of
apoptosis may favor viral dissemination as a result of the dismantlement of the infected cells. Mitochondria
have been long recognized for their key role in the modulation of apoptosis but more recently, mitochondria
have been shown to serve as a crucial platform for innate immune signaling as illustrated by the
identiﬁcation of MAVS. Thus, it is therefore not surprising that this organelle represents a recurrent target for
viruses, aiming to manipulate the fate of the infected host cell or to inhibit innate immune response. In this
review, we highlight the viral proteins that are speciﬁcally targeted to the mitochondria to subvert host
defense. This article is part of a Special Issue entitled Mitochondria: the deadly organelle.ondria: the deadly organelle.
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l rights reserved.© 2010 Elsevier B.V. All rights reserved.Detection of viruses byhost cells relies on several families of pattern-
recognition receptors (PRRs), and these sensors are responsible for the
triggering of innate immune responses. PRRs recognize structures
conserved among microbial species, which are called pathogen-
associated molecular patterns (PAMPs) [1,2]. PRRs are also responsible
for recognizing endogenous molecules released from damaged cells,
the damage (or danger) associated molecular patterns (DAMPs). At the
cellular level, threemain families of PRRs have been characterized in the
past 15 years: the transmembrane Toll-like receptors (TLRs), the
cytosolic Nod-like receptors (NLRs) and the RIG-I-like receptors
(RLRs) [1,2]. In addition, a heterogenous class of cytosolic sensors of
double-stranded DNA is represented by the proteins DAI/DLM1/ZBP1
and AIM2/HIN200, which trigger type I interferon and caspase-1
inﬂammasomepathways, respectively [3]. Upondetection of theviruses
by these PRRs, infected cells trigger a large repertoire of defense
pathways that, together, contribute to cellular innate immunity. These
responses include factors such as NF-κB, IRF (IFN-Regulatory Factor),
JNK, p38 and ERK, which affect inﬂammatory and defense mediators at
the transcriptional level. PRRs also trigger the transcription-indepen-
dent recruitment of the caspase-1 inﬂammasome, resulting in the
maturation of the critical pro-inﬂammatory mediators IL-1β, IL-18 and
IL-33 [4]. Another critical axis of the host response to infection is the
modulation of survival/death pathways. Depending of the nature of thepathogen encountered, the nature of the infected cell, and probably the
intensity of the infection, the cellular responses are tipped either
towards cell death or cell survival [5]. Indeed, theﬁnal fate of an infected
cell is commonly the result of the opposing effects of pro-survival and
pro-death pathways, and in a number of cases, depends on the opposite
actions of the virus and the infected cell. Mitochondria represent a
critical organelle implicated in the induction of programmed cell death
(PCD) and, consequently, play a central role in cellular host–virus
interactions. Therefore, it is not surprising that so many viral strategies
are aiming at targeting mitochondria to subvert PCD.
In addition to the well-documented role of mitochondria in the
induction of PCD following infection, an emerging concept is that this
organelle represents a convergent point of a number of cellular innate
immune responses. This has been remarkably illustrated recently by
the discovery of MAVS (IPS-1/Cardif/VISA), a critical adaptor protein
downstream of the RLR proteins RNA sensors RIG-I and MDA-5 [6–9].
MAVS is anchored to the mitochondrial outer membrane, and this
sub-cellular localization is essential for the function of the protein [8].
These recent observations suggest that the role of mitochondria in the
regulation of cellular responses to viruses may span much beyond the
modulation of PCD. This article reviews how some viral proteins
addressed at the mitochondria subvert host defense either by
modulating PCD or by inhibiting innate immunity.
1. Mitochondrion, a key player in apoptosis
Apoptosis, a form of PCD, is a cell suicide program essential for
development and for adult tissue homeostasis in all metazoan
animals. The misregulation (inhibition or exacerbation) of apoptosis
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generative diseases, cancers and AIDS [10]. The stereotypical death
throes of a cell undergoing apoptosis include DNA fragmentation,
nuclear condensation, cell shrinkage, blebbing and phosphatidylser-
ine externalization; these features are closely associated with the
activity of a family of cysteine proteases called caspases [11].
Caspases are a family of cysteine proteases involved in the
transduction and execution of the apoptotic program [10]. Caspases
are produced as pro-enzymes that must be proteolytically cleaved to
produce active caspases. Caspases are classiﬁed in two groups: the
initiator caspases such as caspase-9 and caspase-8 and the effector
caspases such as caspase-3.
Mitochondria are implicated in the twomajor apoptotic pathways.
The death receptor-mediated pathway (“extrinsic pathway”) involves
mitochondria mainly as an ampliﬁcation loop, whereas cellular
deprival and stress-mediated apoptosis is regulated predominantly
at the mitochondrial level (“intrinsic pathway”). Mitochondria have a
pivotal role in apoptosis by releasing apoptogenic factors such as
cytochrome c, Smac/DIABLO and Omi/HtrA2 [12] (Fig. 1). In the
cytosol, cytochrome c triggers caspase activation following the
formation of a ternary complex called the apoptosome that is
composed of the adaptor protein Apaf-1, caspase-9 and cytochrome
c [11]. In the apoptosome, active initiator caspase-9 processes effector
caspases such as caspase-3. Next, active caspase-3 cleaves several cell
substrates to induce apoptosis and cell death [11]. Natural inhibitors
of caspases are found in cells, the X-linked inhibitor of apoptosis
proteins (XIAP) [13], and the function of Smac/DIABLO and Omi/
HtrA2 once released into the cytosol is to antagonize XIAP to promote
caspase activation. Bcl-2 family members regulate mitochondrial
outermembrane permeabilization (MOMP), resulting in the release of
cytochrome c, Smac/DIABLO and Omi/HtrA2 and subsequent caspase
activation. The Bcl-2 family includes pro- and anti-apoptotic proteinsFig. 1. The central role of mitochondrion in apoptosis and modulation by viral proteins.
mitochondrial apoptogenic factors (cytochrome c, Smac/Diablo, Omi/HtrA2) involved in cas
apoptotic Bcl-2 members (Bcl-2 and Bcl-XL). In blue, the viral Bcl-2 homologues (vBcl-2) w
vBcl-2 s with structure homology with Bcl-2. Abbreviations: ADV, adenovirus; EBV, Epste
herpesvirus saimiri; PPVO, parapoxvirus ORF virus; FPV, fowlpox virus; ASFV, African swin[14]. Anti-apoptotic proteins such as Bcl-2 or Bcl-XL inhibit the
function of pro-apoptotic proteins such as Bax or Bak. Bcl-2 family
members contain conserved domains (the Bcl-2-homology domains
named BH1 to BH4), and these domains are required for the pro- or
anti-apoptotic function of the protein. An important subgroup of pro-
apoptotic Bcl-2members is the ‘BH3-only’ proteins, so named because
they only have a BH3 domain. The ‘BH3-only’ proteins (Bik, Bid, Bim,
Bad, Puma, NoxA, Hrk, Bmf) have a pro-apoptotic function by either
activating the pro-apoptotic members (Bax and Bak) or by inhibiting
the anti-apoptotic members (Bcl-2, Bcl-XL, A1, Mcl-1) [15]. The
mechanisms by which the pro-apoptotic Bcl-2 family members
induce MOMP remain controversial and not fully understood [16].
One proposed model focuses on the rupture of the outer mitochon-
drial membrane as a consequence of mitochondrial matrix swelling
following the opening of the permeability transition pore (PTP), a
putative pore composed, at least, by the channel VDAC, the adenine
nucleotide translocator ANT and cyclophilin D [17]. According to
anothermodel, pro-apoptotic Bcl-2 proteins such as Bax or Bak induce
a selective process of MOMP through the formation of channels or
pores, enabling the selective release of proteins that are soluble in the
IMS such as cytochrome c [18].
Besides apoptosis, a number of other cell death pathways have
been described [19]. These other cell death pathways are autophagic
cell death (for review see [20]), necroptosis (a form of regulated
necrosis) and PARP-1-mediated necrotic death [19]. Necrosis, unlike
apoptosis, is considered as an unregulated cell death caused by
overwhelming stress that is incompatible with cell survival. Again,
mitochondria have been reported to play a role in necroptosis and
necrosis through the production of ROS following disruption of the
association of ADP-ATP translocase (ANT) with cyclophilin D, or
through the release into the cytosol of caspase-independent cell death
effectors such as AIF [12].Pro-apoptotic Bcl-2 members (Bax and Bak) promote the release into the cytosol of
pase activation. The pro-apoptotic function of Bax and Bak is antagonized by the anti-
ith sequence homology with Bcl-2 that inhibit apoptosis of infected cells. In purple, the
in–Barr virus; HHV-8, human herpesvirus 8; γHV-68, murine γ-herpesvirus 68; HVS,
e fever virus; VACV, vaccinia virus; MXV, myxoma virus, CMV, cytomegalovirus.
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Elimination of infected cells through apoptosis is one of the most
ancestral defense mechanisms against infections, hence neutralizing
host cell apoptosis represents a required step for viral replication [21].
Throughout the process of pathogen–host co-evolution, viruses have
therefore acquired distinct strategies to neutralize immunity in
infected hosts and they have developed the capability of inhibiting
host cell apoptosis. Conversely, viruses may take advantages of
promoting apoptosis, either to induce the breakdown of infected cells
thereby favoring viral spreading or to kill uninfected cells of the
immune system [21].
Several proteins encoded by viral genome are homologues of the
host regulators of apoptosis such as Bcl-2 family members but key
components of the apoptotic machinery are also speciﬁcally targeted
by viral factors with no homology to host proteins. So viral proteins
that regulate mitochondria-mediated apoptosis can be classiﬁed into
the following subgroups: anti-apoptotic proteins (1) that share
sequence and/or structural similarity to anti-apoptotic Bcl-2 family
members (so-called viral Bcl-2 proteins or vBcl-2 s) or pro-apoptotic
modulators (2) that directly insert into mitochondrial membranes to
triggerMOMP. A number a viral factors also inhibit apoptosis via other
mechanisms which do not directly involve the Bcl-2 system and
mitochondria (for review see [22]).
3. Viral inhibitors of apoptosis
3.1. Viral Bcl-2 homologs (vBcl-2) with sequence homology with Bcl-2
Prevention of apoptosis of the infected cells is a way for a virus to
sustain its replication but it is also required for the establishment and/
or the maintenance of the latency or the persistence of the virus. So
viruses have selected a battery of Bcl-2 homologs that mimic the anti-
apoptotic machinery of host cell.
The ﬁrst indication that viruses encode Bcl-2 functional homologs
and that their manipulation of apoptosis is a requirement for normal
productive infection came from observations made with adenovirus-
infected cells. Human adenoviruses (ADV) are DNA virus pathogens,
some of which are the cause of as much as 10% of all childhood
pneumonias, whereas other cause conjunctivitis and outbreaks of
acute respiratory disease. One of the oncogenes of adenovirus (ADV),
E1B-19K,was shown to be required to prevent apoptosis and enhanced
cytopathic effects duringproductive virus infection suggesting that the
E1B-19K protein may function as an apoptosis inhibitor in produc-
tively infected human cells [23]. E1B-19K and Bcl-2 can functionally
substitute for one another in the suppression of apoptosis during virus
infection and oncogenic transformation, indicating that viruses did,
indeed, see ﬁt to encode inhibitors of apoptosis [24–26]. Moreover,
E1B-19K inhibits cell death induced by a plethora of stimuli, including
E1A-triggered activation of p53, growth factor deprivation, ligation of
TNFR, Fas and TRAIL receptor 1 (TRAIL-R1) at the plasma membrane
and heterologous Bax expression [27]. While E1B-19K and Bcl-2 share
a limited sequence similarity [24], E1B-19K possesses a BH1, BH2 and
BH3 domain as well as a transmembrane domain and the most
conserved residues in the dozen or so viral serotypes in which the
sequence of E1B-19K is known are also conserved in Bcl-2 [21,24].
Similar to Bcl-2, a large fraction of E1B-19K is located at mitochondria
where it inhibits apoptosis by sequestering pro-apoptotic members of
the Bcl-2 family such as Bax [28–30], Bak [28] and Bnip3 [31]. Notably,
several Bcl-2 family proteins such as Bak, Bik and the putative BH3-
only proteins Bnip3 and Nip3L have been originally identiﬁed through
their interaction with E1B-19K [21].
Epstein–Barr virus (EBV) is a prominentmember ofγ herpesviruses,
invading primary resting B lymphocytes to establish a latent infection
that eventually culminates in cell transformation. Coordinated expres-
sion of anti-apoptotic proteins BHRF1 and BALF1 with other severalgene products leads to the potent mitogenic effect of EBV [32]. BHRF1
and BALF1 share sequence and structure homology with Bcl-2 and
hence are vBcl-2 s [33,34].Whereas BHRF1 clearly resembles Bcl-2 in its
anti-apoptotic role [35], the function of BALF1 is controversial. Indeed,
BALF1 is capable of interacting with Bax and Bak [34] but another study
suggests that BALF1 is a BHRF1 antagonist. However, BALF1 is actively
expressed in EBV-positive Burkitt lymphoma's cell lines and nasopha-
ryngeal carcinoma biopsies and renders cells independent from serum
suggesting a prominent anti-apoptotic (rather than pro-apoptotic)
function for BALF1 during EBV-driven tumorigenesis [36]. Importantly,
anti-apoptotic proteins appear to be essential in the early phases of the
herpesvirus life cycle, as for other DNA viruses. The C-terminal
hydrophobic domain of BHRF1 is required for its mitochondrial
localization at the outer membrane and it exhibits high levels of
homology with several Bcl-2 family members [37]. Furthermore, the
3-dimensional structure of BHRF1 is very similar to that of Bcl-2 since it
contains two central hydrophobic α-helices that are surrounded by
several amphipathicα-helices.While initial studies have described that
BHRF1 does not seem to be capable of binding and inhibiting BH3-only
proteins, presumably because it lacks an exposed pre-formed BH3
binding groove [33,37], two recent papers have shown that BHRF1 can
actually bind to Bim or BH3 domain peptides [38,39]. BHRF1 efﬁciently
prevents MOMP and ensuing apoptosis induced by several differ-
ent stimuli such as DNA damaging agent, death receptors ligation
leading, c-myc activation, heterologous viral infection, granzyme B, γ
irradiation or chemotherapeutic drugs [22]. Surprisingly, BHRF1 (but
not Bcl-2) overexpression has been reported to trigger a rapid transit
through the cell cycle suggesting yet another mechanism by which this
protein might contribute to EBV-induced tumorigenesis [40].
BHRF1 is highly conservedbothat the sequence and functional levels
in EBV analogues infecting baboons (herpesvirus papio) and chimpan-
zees (herpesvirus pan) [41] as well as in different EBV isolates [42]. This
suggests therefore that BHRF1 plays a signiﬁcant, evolutionarily
conserved function in vivo. In accord, herpesvirus papio BHRF1
(hpoBHRF1) is a 17-kDa protein that shares 64% sequence identity
and 79% sequence similarity with BHRF1 from EBV. HpoBHRF1 and
BHRF1 similarly protected human keratinocytes against cisplatin-
induced apoptosis in functional assays [43]. Finally, herpesvirus pan-
encoded BHRF1 (hpnBHRF1) acts like EBV BHRF1 in protecting a human
Burkitt lymphoma cell line against apoptosis induced by UV irradiation,
etoposide and serum withdrawal [44].
Other vBcl-2 s have been described in the herpesvirus family such
as the Kaposi sarcoma-associated Bcl-2 (KSBcl-2), γHV-68 M11 and
HVS ORF16 that were identiﬁed in human herpesvirus 8 (HHV-8),
murine γ-herpesvirus 68 (γHV-68) and herpesvirus saimiri (HVS),
respectively [45–47]. HHV-8 ORF16 encodes the so-called Kaposi
sarcoma-associated Bcl-2 (KSBcl-2). Overexpression of KSbcl-2 blocks
apoptosis as efﬁciently as Bcl-2, Bcl-XL or BHRF1 [45]. KSBcl-2 is a
protein sharing limited (about 15–20%) overall sequence identity
with other Bcl-2 family members such as Bcl-2, Bcl-XL, Bax and Bak as
well as BHRF1 [45]. Signiﬁcant amino acid identity is concentrated in
the BH1 and BH2 domains but curiously not in the BH3 domain. KSBcl-
2 structure is almost identical to that of Bcl-2/Bcl-XL but important
differences were found in the lengths of helices and loops [48]. In
consequence, KSBcl-2 is not capable of forming homodimers or
heterodimers with Bcl-2 family members that may be explained by
the dissimilarity in sequence and structure with Bcl-2 [45,48]. The
observation that KSBcl-2 neither homodimerizes or heterodimerizes
suggests that this protein may have evolved to escape any negative
regulatory effects mediated by host pro-apoptotic Bcl-2 members
[45,48].
γHV-68 M11 is a protein that unlike most of the other vBcl-2 s,
which have both BH1 and BH2 domains conservedwith respect to Bcl-
2, has a BH1 domain, but apparently lacks a BH2 domain [47]. In spite
of this, M11 has been reported to inhibit Fas and TNFα-induced
apoptosis in cell lines [47] as well as Bax toxicity in yeast [49]. Nuclear
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BH3 binding groove that binds BH3 domain peptides of Bax and Bak
via a molecular mechanism shared with host Bcl-2 family proteins,
involving a conserved arginine in the BH3 peptide binding groove.
Mutations of this conserved arginine within the BH3 binding groove
results in a properly folded protein that lacks the capacity of the wild-
type M11 to bind Bax BH3 peptide and to block Bax toxicity in yeast
[49]. Importantly, viruses harboring the same mutation exhibit
impaired persistent replication and reactivation from latency in vivo
pointing therefore a major role of M11 for the establishment of a
persistent viral pool and chronic infection [49] rather than for viral
replication and virulence during acute infection as initially proposed
[50]. Finally, it has been reported that M11 inhibits autophagy
through the binding of its hydrophobic surface groove to the BH3
domain of Beclin1, a key autophagy effector [51].
HVS ORF16 protects cells from heterologous virus-induced
apoptosis. Unlike KSBcl-2, ORF16 heterodimerizes with Bax and Bak.
The BH1 and BH2 homology domains are highly conserved in ORF16
but it lacks the core sequence of the conserved BH3 homology domain,
suggesting that this region is not essential for the anti-apoptotic
activity [46]. Like BHRF1 or KSBcl-2, ORF16 contains conserved
hydrophobic residues in its C-terminus required for its insertion
into mitochondrial outer membrane [45]. Interestingly, while some
mammalian anti-apoptotic Bcl-2 can be converted into pro-apoptotic
factors by caspases during apoptosis, several herpesvirus-encoded
vBcl-2 cannot, therefore failing to display any latent pro-apoptotic
function [52].
In addition to KSBcl-2, HHV-8 also expresses another protein with
very limited homology to Bcl-2 [53]. K7 is a 16-kDa glycoprotein
structurally related to survivin-DeltaEx3, a splice variant of human
survivin that protects cells from apoptosis by an undeﬁnedmechanism.
Both K7 and survivin-DeltaEx3 contain a mitochondrial targeting
sequence, an N-terminal region of a BIR (baculovirus IAP repeat)
domain and a putative BH2 domain. K7 efﬁciently inhibits apoptosis
induced by several stimuli (death receptors activation, ER stress or Bax
expression) and anchors to intracellular membranes where Bcl-2 re-
sides. K7 does not associate with Bax, but does bind to Bcl-2 via its
putative BH2domain. In addition, K7binds to active caspase-3 via its BIR
domain and thus inhibits the activity of caspase-3. The BH2 domain of
K7 is crucial for the inhibition of caspase-3 activity and is therefore
essential for its anti-apoptotic function. Furthermore, K7 bridges Bcl-2
and activated caspase-3 into a protein complex. K7 therefore appears to
be an adaptor protein and part of an anti-apoptotic complex that
presents effector caspases to Bcl-2, enabling Bcl-2 to inhibit caspase
activity. Due to its molecular structure, K7 can be considered either as a
viral IAP (vIAP) or as a vBcl-2 [53].
Poxviruses cause several diseases of humans and domestic animals
including smallpox, cowpox, sheeppox, fowlpox and goatpox and
recently two novel vBcl-2 inhibitors of apoptosis encoded by poxvirus
have been discovered: FPV039 from fowlpox virus (FPV) [54] and
ORFV125 from parapoxvirus ORF virus (PPVO) [55].While FPV039 has
limited homology with Bcl-2, it inhibits apoptosis in response to a
variety of cytotoxic stimuli, including virus infection itself. Similar to
other anti-apoptotic Bcl-2 proteins, FPV039 localizes predominantly
to the mitochondria in both human and chicken cells. In addition,
FPV039 interacts constitutively with Bak.Moreover, FPV039 is capable
of substituting for F1L (another vBcl-2 encoded by vaccinia virus,
VACV, see below) in inhibiting Bak activation and apoptosis triggered
by staurosporine or VACV infection, conﬁrming that FPV039 is a
functional homolog of F1L and is therefore a vBcl-2 [54]. FPV039
inhibits apoptosis induced by Bax overexpression as well and
prevents both the conformational activation of Bax and the subse-
quent formation of Bax oligomers at the mitochondria, two critical
steps in the induction of apoptosis. Additionally, FPV039 interacts
with activated Bax in the context of Bax overexpression and virus
infection. Importantly, the ability of FPV039 to interact with active Baxand to inhibit Bax activity is dependent on the structurally conserved
BH3 domain of FPV039, even though this domain possesses little
sequence homology to other BH3 domains. FPV039 also inhibits
apoptosis induced by the “BH3-only” proteins, upstream activators of
Bak and Bax, despite interacting detectably with only two: Bim and
Bik [56]. In UV-irradiated HeLa cells, ORFV125 fully inhibits DNA
fragmentation, caspase activation and cytochrome c release. The
mitochondrial localization of ORFV125 is determined by a distinctive
C-terminal domain, and is required for its anti-apoptotic function. As
assessed by bioinformatic analyses, ORFV125 shares sequence and
structure similarities with anti-apoptotic members of the Bcl-2 family
(i.e., Bcl-2, Bcl-XL and Bcl-w). Accordingly, ORFV125 inhibits the UV-
induced activation of Bax and Bak [55]. Furthermore, ORFV125
interacts with a range of “BH3-only” proteins (Bik, Puma, Hrk, Noxa
and Bim) and neutralizes their pro-apoptotic activity. In addition,
ORFV125 binds to the active, but not the inactive, form of Bax, and
reduces the formation of Bax dimers. Mutation of speciﬁc amino acids
in ORFV125 that are conserved and functionally important in
mammalian Bcl-2 family proteins leads to loss of both binding and
inhibitory functions [57]. Altogether, these observations conﬁrm the
idea that ORFV125 represents a new member of the vBcl-2 family.
To avoid premature apoptosis of the host cell, African swine fever
virus (ASFV) expresses multiple anti-apoptotic proteins such as the
vBcl-2 family member A179L (also called 5-HL) [58,59]. A179L codes
for a 21-kDa protein that contains all known domains associated with
Bcl-2 structural and functional features, including those mediating
protein-binding (i.e., homo- and heterodimerization) and regulating
cell death [58]. Thus, A179L has been shown to suppress apoptosis
induced by multiple stimuli [58,59].
Nine vBcl-2 s sharing sequence homologies (specially at the BH
domains)withBcl-2havebeendescribed so far (Fig. 1) [22].While some
of them have been reported to directly bind Bax and/or Bak (E1B-19K,
BALF1, ORF16 or FPV039), they presumably all act like anti-apoptotic
Bcl-2members [39] by inhibiting and sequestering activator(s) of Baxor
Bak like the “BH3-only” proteins Bim and tBid [14] to prevent MOMP
and ensuing apoptosis.
3.2. vBcl-2 with structure homology with Bcl-2
Other viral factors are also classiﬁed as vBcl-2, not because they
share sequence homologies with Bcl-2 (for instance presence of “BH
domains”) but rather because they fold like Bcl-2 and exert similar
anti-apoptotic properties [22].
Human cytomegalovirus (CMV) is a member of the β herpes-
viruses and it is a major cause of mortality in immuno-compromised
individuals (organ transplant recipients and patients with AIDS). CMV
is also a major cause of congenital disease during pregnancy. Human
CMV encodes several proteins that subvert host cell function to favor
viral replication. The best characterized is vMIA (viral mitochondria-
localized inhibitor of apoptosis), the product of the CMV gene UL37
(pUL37x1) [60]. vMIA is required for viral replication and it inhibits
apoptosis induced by diverse stimuli such as death receptor ligation,
treatment with cytotoxic agents as well as infection with a mutant
ADV strain lacking the vBcl-2 E1B-19K [60,61]. vMIA exerts its anti-
apoptotic activity by inhibiting MOMP at the mitochondrial level
although vMIA does not share any obvious similarity with Bcl-2 or
vBcl-2 [60]. vMIA is inserted into the mitochondrial outer membrane
and importantly vMIA selectively binds/sequesters and inactivates
Bax but not Bak to prevent MOMP [61]. The observation that the anti-
apoptotic function of vMIA is lost in Bax-deﬁcient cells conﬁrms that
vMIA selectively acts on Bax to prevent apoptosis [61]. It appears that
both mitochondrial targeting sequence and Bax-binding domain are
required and sufﬁcient for vMIA to prevent Bax activation [61].
The structure–function relationship of the Bax/vMIA interaction has
been addressed by mutational and computational analyses, suggest-
ing a model in which the overall fold of vMIA closely resembles that of
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bind to the BH3 domain of Bax but rather engages electrostatic
interactions involving a region of Bax between its BH2 and BH3
domains [62]. This region is not conserved in Bak, explaining why
vMIA (unlike Bcl-XL) fails to interact with Bak [61,62]. Besides its anti-
apoptotic function through the neutralization of Bax, vMIA also
induces the release of ER Ca2+ stores into the cytosol [63] and triggers
fragmentation of the mitochondrial network [64]. Interestingly,
fragmentation of the mitochondrial network following vMIA expres-
sion seems to be responsible for an inhibition of the innate anti-virale
immunity [65] (see below).
Murine CMV also expresses a vBcl-2, termed m38.5. m38.5 is in a
similar position in the murine cytomegalovirus (MCMV) genome than
vMIA inhumanCMV.Whilem38 .5 is unrelated to vMIA in its aminoacid
sequence, it also inhibits death receptor ligation-induced apoptosis.
m38.5 associates with Bax, recruits it to mitochondria, and blocks Bax-
mediated but not Bak-mediated MOMP [66]. Thus, primate and murine
CMVs have evolved non-homologous but functionally similar cell death
suppressors selectively targeting the Bax-mediated branch of the
mitochondrial apoptotic signaling pathway [66]. While some viruses
express vBcl-2 that inhibits apoptosis by preventing activation and/or
oligomerization of the pro-apoptotic proteins Bax and Bak, it seems that
CMVs have adopted a different strategy. Indeed, a recent report
demonstrates that they encode two separate mitochondrial proteins
that lack obvious sequence similarities to Bcl-2-family proteins and
importantly speciﬁcally counteract either Bax or Bak [67]. In addition of
m38.5, MCMV open reading frame (ORF) m41.1 encodes for a small
mitochondrion-localized protein which functions as a viral inhibitor of
Bak oligomerization (vIBO). vIBO blocks Bak-mediated cytochrome c
release and Bak-dependent induction of apoptosis. It protects cells from
cell death-inducing stimuli together with vMIA. Similar vIBO proteins
are encoded by CMVs of rats, and possibly by other CMVs as well [67].
These results suggest a non-redundant function of Bax and Bak during
viral infection, and a beneﬁt for CMVs derived from the ability to inhibit
Bak and Bax separately with two viral proteins.
The genome of many poxviruses encodes for proteins that despite
the lack of sequence similarity, fold like Bcl-2, prevent apoptosis and
are therefore considered as vBcl-2 s. F1L from VACV is responsible for
the inhibition of apoptosis [68]. Indeed cytochrome c release and
ensuing caspase activation do not occur in VACV infected cells. In
contrast, a vaccinia virus deletion mutant, VV811, is unable to inhibit
apoptosis; however, the anti-apoptotic function was restored by
expression of the F1L ORF. Although F1L displays no homology to
members of the Bcl-2 family, it localizes to the mitochondria through
a C-terminal hydrophobic domain [68]. Importantly F1L directly
interacts with the BH3 domain of pro-apoptotic Bcl-2 members such
as Bak and Bim [69,70]. While F1L inhibits mitochondrial transloca-
tion and activation of Bax, F1L does not bind to Bax suggesting that F1L
acts upstream of Bax activation [70]. Finally, other poxviruses (variola
virus, monkeypoxvirus and ectromelia virus) encode functional F1L
orthologs [68].
Myxoma virus (MXV) is a leporipoxvirus causing myxomatosis in
rabbit. Productive infection by MXV requires the expression of
M11L, a protein with no deﬁned structural motifs except a putative
C-terminal TM domain that resembles that of some members of the
Bcl-2 family [71]. From its mitochondrial localization, M11L sup-
presses apoptosis induced by treatment with staurosporine [71],
overexpression of Bak [72] and viral infection [73]. M11L constitu-
tively interacts with Bax and Bak to prevent MOMP [74]. Bax-
mediated apoptosis is blocked in MXV-infected cells lacking Bak
expression, suggesting that M11L interacts with Bax independently
from Bak [73]. M11L may also inhibit PTP opening to prevent
apoptosis [71]. M11L has no obvious sequence homology with Bcl-2
or Bcl-XL, yet adopts a virtually identical three-dimensional fold [75]
allowing this protein to associate with a peptide derived from the BH3
domain of Bak with an afﬁnity comparable to that of Bcl-2 and Bcl-XLfor the same peptide [75]. For all these reasons, M11L represents a
structural mimic of Bcl-2 and hence a bona ﬁde vBcl-2 [74].
N1L is the most potent virulence factor of VACV and is required for
productive replication in vivo [76]. During viral infection, N1L binds to
endogenous pro-apoptotic Bcl-2 family members such as Bax, Bak and
Bid [77]. Like M11L, N1L shares no sequence homology with cellular
proteins however it exhibits a three-dimensional structure that closely
mimics that of Bcl-2 and Bcl-XL [78]. So the surface of N1L possesses a
constitutively open groove common to other anti-apoptoticmembers of
the Bcl-2 family, which mediates the interaction with BH3-containing
proteins [77]. The examples provided by M11L and N1L illustrate the
importance of the conservation of structure, rather than of primary
amino acid sequence, for the maintenance of protein function along
evolution.
4. Viral pro-apoptotic factors
Hepatitis B virus (HBV) is one of the most prominent etiological
agents of chronic liver disease and persistent infection is associated
with hepatocellular carcinoma. HBV X protein (HBx) is involved in
viral replication and exhibits an oncogenic potential in animal models
[79]. HBx is addressed at the mitochondria where it induces
aggregation of these organelles and where it interacts with VDAC3
to promote ΔΨm loss and ensuing apoptosis [80]. Interestingly HBx
sensitizes cells to apoptosis induced by TNFα [81]. Mutagenesis
studies revealed that a putative transmembrane region (aa 54–70)
rather than its transactivation domain is required for its mitochon-
drial localization and ΔΨm loss [80].
Poliovirus (PLV) infection causes paralytic poliomyelitis, an acute
disease resulting in ﬂaccid paralysis associated with apoptosis of
motor neurons. Similar to HBx, viroporin 2B of PLV localizes to
mitochondria, alters their morphology, induces a perinuclear redis-
tribution ofmitochondria and promotes caspase-dependent cell death
[82]. OrfC protein from the Walleye dermal sarcoma virus (WDSV)
and E1E4 from the human papillomaviruses (HPVs) also affect
mitochondrial morphology and distribution followed by dissipation
of ΔΨm and apoptosis [83,84]. WDSV is a retrovirus causing benign
tumors in ﬁsh whereas HPVs are responsible for a broad range of
infectious diseases, ranging from anogenital warts (e.g., HPV-6 and
-11) to progressive dysplastic-neoplastic lesions of the genital mucosa
(e.g., HPV-16 and -18). Both OrfC and E1E4 localize to mitochondria
but while E1E4 associates to mitochondria due to an N-terminal
leucine-rich region, OrfC does not seem to possess any homology to
known mitochondrial targeting sequence [83,84].
Retroviruses like the human immunodeﬁciency virus 1 (HIV-1) or
the human T lymphotropic virus 1 (HTLV-1, involves in neurogen-
erative and lymphoproliferative disorders, notably acute T cell
leukemia) also express proteins with pro-apoptotic activity. For
HIV-1, this contributes to the depletion of CD4+ T lymphocytes that is
observed during AIDS. The viral protein R (Vpr) from HIV-1 has a
direct mitochondrial effect because it interacts with ANT and VDAC,
thereby promoting PTP opening leading to MOMP associated with
ΔΨm loss, release of mitochondrial apoptogenic factors and caspase
activation [85,86]. pl3(II) protein from HTLV1 is also targeted to
mitochondria where it induces a rapid ﬂux of ions across inner
membrane together with swelling, ΔΨm dissipation and mitochon-
drial fragmentation [87].
PB1-F2 is a protein encoded by inﬂuenza A virus (IAV) that
determines virulence in murine models of infection. PB1-F2 inserts
intomitochondrial outermembrane via its C-terminus and there, PB1-
F2 acquires a pore forming activity similar to the pore forming activity
displayed by pro-apoptotic Bcl-2 members, such as Bax, to promote
MOMP [88,89]. Moreover, PB1-F2 interacts with VDAC and isoform 3
of ANT (ANT3) suggesting that PB1-F2 may also promote MOMP
through PTP opening [90]. Finally, other viral proteins such as VP3 and
2C from the avian encephalomyelitis virus (AEV) and the non-
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found associated to the mitochondria and promote MOMP through an
unknown mechanism [91–93].
In summary, manipulation of mitochondrial-mediated apoptosis is
a common theme for several viruses and it can determine the
outcome of the infectious process. Even though mitochondrial
dysfunction has been historically associated with apoptosis, it is
actually a crucial checkpoint for different modalities of cell death,
including necrosis and autophagy.
5. Mitochondrion, a recruitment platform in the RIG-I-like
receptor pathway
In 2004, a new pathway and TLR-independent response to virus
was uncovered with the discovery of RIG-I-like receptors (RLR)
proteins [1,94]. This family of cytosolic PRRs is composed of 3
molecules: retinoic acid inducible gene-I (RIG-I), melanoma differ-
entiation-associated gene-5 (MDA-5) and laboratory of genetics and
physiology 2 (LGP2). RIG-I and MDA-5 are both prototypical PRR
factors whereas LGP2 acts likely as an activator of RIG-I [1,95].
RIG-I and MDA-5 are both cytosolic helicases with ATPase activity
and they contain a C-terminal regulatory domain required for the
binding to viral RNA. Importantly, the N-termini of RIG-I and MDA-5,
but not LGP2, contain 2 tandem CARD domains [1]. The ATPase
activity of both helicases as a result of binding to their ligands may be
critical not only for translocation along dsRNA [96], but also for
conformational changes that lead to the exposure of the CARDs
masked by the C-terminal regulatory domain. This conformational
change is required for the interaction between the 2 CARD domains
of RIG-I and MDA-5 with the CARD domain of mitochondrial anti-
viral signaling protein (MAVS; also known as CARDIF, IPS-1 or VISA)
[6–9], a protein inserted in the mitochondrial outer membrane
through a transmembrane domain in its C-terminal region [8].Fig. 2. Overview of the RIG-I-like receptors pathway. In the cytosol, viral RNAs are recogniz
domain that interact with the CARD domain of the mitochondrial adaptor MAVS. MAVS, af
NF-κB activation leading to the production of type I IFNs and pro-inﬂammatory cytokineAlthough this interaction results in propagation of downstream sig-
naling, the mechanism by which the signal is transduced remains
poorly elucidated.
Following theMAVS/RIG-I or MAVS/MDA-5 association, MAVSwas
found to associate with TNF-receptor-associated factor (TRAF) 3, an
E3 ubiquitin ligase assembling lysine 63-linked polyubiquitin chains,
through its C-terminal TRAF domain [97]. TRAF3−/− cells show
severely impaired production of type I IFNs in response to virus
infection [98]. TRAF3 recruits and activates two “noncanonical” IKK-
related kinases, designated TANK-binding kinase 1 (TBK1) and
inducible IkB kinase (IKK-i), which phosphorylate IRF-3 and IRF-7
(Fig. 2). TBK1 and IKK-i (also named IKK-ε) interact with TRAF family
member associated NF-kB activator (TANK) and NAK-associated
protein 1 (NAP1). Phosphorylation of IRF-3 and IRF-7 by these kinases
induces the formation of homodimers and/or heterodimers, which
translocate into the nucleus and bind to IFN-stimulated response
elements (ISREs), thereby resulting in the expression of type I IFN
genes and a set of IFN-inducible genes. Finally, the NF-κB modulator
NEMO (IKKγ) has been shown to be essential for the signal
transduction downstream of the complex formed by TBK1, IKK-i,
TANK and NAP1 (Fig. 2) [99].
In co-immunoprecipitation experiments, MAVS has also been
reported to interact with TRAF6 [8,9], which in a complex with
transforming growth factor beta-activated kinase 1 (TAK1) and TAK1-
binding protein 2 and 3 (TAB2 and TAB3) leads to NF-κB activation
[100]. In addition, FAS-associated death domain-containing protein
(FADD) is found in a complex with MAVS [6] and the FADD/caspase8-
dependent pathway could be required for the activation of NF-κB
downstream of MAVS [101]. Importantly, FADD have been demon-
strated to be important in innate anti-viral immunity since FADD−/−
cells are defective in type I IFNs production [102]. Finally, TRADD, a
crucial adaptor of tumor necrosis factor receptor (TNFRI), is recruited
to MAVS and orchestrated complex formation with TRAF3, TANK anded by the helicases RIG-I or MDA-5. The N-termini of RIG-I and MDA-5 contain 2 CARD
ter recruitment of transactivators, then induces phosphorylation of IRF3 and IRF7 and
s, respectively.
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Accordingly, TRADD−/− cells show a reduced production of type I
IFNs in response to RNA viruses [103].
Although the links between MAVS and the downstream transacti-
vators mentioned above (Fig. 2) are not fully understood, the recent
discovery of STING (also called MITA) [104,105], has added an
important new factor to this pathway. Two groups have reported that
this protein interacts with both MAVS and RIG-I and is required for
signaling through these molecules [104,105]. Results by Ishikawa and
Barber suggest that STING acts downstream of RIG-I and MAVS [104].
Surprisingly, STING is found at the endoplasmic reticulum and co-
immunoprecipitates with SSR2 (also known as TRAPβ), a member of
the translocon-associated protein (TRAP) complex required for
protein translocation across the ER membrane following translation.
The translocon associates with the exocyst that can associate with
TBK1 leading to the hypothesis that RIG-I binds to translating viral
RNAs at the translocon and signals through STING to exocyst-
associated TBK1 [104]. Importantly, STING is not only required for
immune responses against certain RNA virus but STING seems to play
a critical role in type I IFN induction by double-stranded B-form DNA
in the cytosol [104,105].6. Viral control of mitochondria-mediated anti-viral
innate immunity
During evolution, viruses have selected/acquired distinct strate-
gies to neutralize immunity in infected hosts [106]. In this review,
only the viral proteins targeted to mitochondria to prevent mito-
chondria-mediated anti-viral innate immunity are detailed.
As mentioned above, MAVS is localized in the mitochondrial outer
membrane and must be localized at the mitochondria to exert its
function [8]. One strategy that HCV employs to establish chronic
infection is to use the viral Serine protease NS3/4A to cleave some
unknown cellular targets involved in innate immunity. Recent studies
have shown that one of the targets of NS3/4A is MAVS. NS3/4A cleaves
MAVS at Cys-508, resulting in its inactivation as a consequence of the
dislocation of the N-terminal fragment of MAVS from the mitochon-
dria. Remarkably, a point mutation of MAVS at Cys-508 renders MAVS
resistant to cleavage by NS3/4A, thus maintaining the ability of MAVS
to induce interferons in HCV replicon cells. NS3/4A binds to and
colocalizes with MAVS in the mitochondrial membrane, and it can
cleave MAVS directly in vitro [7,107]. Identical observations were
made with GB virus B (GBV-B) [108], phylogenetically the closest
related virus to HCV which causes generally acute and occasionally
chronic hepatitis in small primates. Similarly, hepatitis A virus (HAV),
a hepatotropic picornavirus, ablates type 1 IFN responses by targeting
the 3ABC precursor of its 3C(pro) cysteine protease to mitochondria
where it colocalizes with and cleaves MAVS, thereby disrupting
activation of IRF3. The 3ABC cleavage of MAVS requires both the
protease activity of 3C(pro) and a transmembrane domain in 3A that
directs 3ABC to mitochondria. Lacking this domain, mature 3C(pro)
protease is incapable of MAVS proteolysis [109].
The PB2 subunit of the inﬂuenza virus RNA polymerase is one of
the virulence determinant of inﬂuenza viruses. Very recently, it was
reported that in addition to its nuclear localization, PB2 accumulated
in the mitochondria where it interacts and inhibits MAVS [110]. The
authors also observed that the PB2 proteins of seasonal human
inﬂuenza viruses localize to the mitochondria, unlike the PB2 proteins
of avian inﬂuenza viruses. This difference in localization is explained
by a single amino acid polymorphism in the PB2 mitochondrial
targeting sequence. While the generation of two recombinant
human inﬂuenza viruses encoding either mitochondrial or non-
mitochondrial PB2 proteins shows that the mitochondrial localization
of PB2 has no impact on viral growth in cell culture, in an animal
model, the virus expressing the non-mitochondrial PB2 proteinsinduces higher production of IFN-β and appears attenuated in
comparison to the virus expressing the mitochondrial PB2 [110].
Hepatitis B virus X (HBX) has been initially described as a pro-
apoptotic protein [80,81] (see above) but a very recent study has
demonstrated that HBX interacts with MAVS and promotes the
degradation of MAVS through Lys(136) ubiquitin in MAVS protein,
thus preventing the induction of IFN-β [111]. Analysis of clinical
samples reveals that MAVS protein is downregulated in hepatocellu-
lar carcinomas of HBV origin, which correlates with increased sen-
sitivities of primary murine hepatocytes isolated from HBX knock-
in transgenic mice upon vesicular stomatitis virus (VSV) infections
[111].
In a recent study, we highlighted a link between mitochondrial
dynamics and RLR [65]. Indeed, we observed that RLR activation
promotes elongation of the mitochondrial network. Mimicking this
elongation enhances signaling downstream fromMAVS and favors the
binding of MAVS to STING. By contrast, enforced mitochondrial
fragmentation dampens signaling and reduces the association
between both proteins. Our ﬁnding that MAVS is associated with a
pool of mitofusin 1, a protein of the mitochondrial fusion machinery,
suggests that MAVS is capable of regulating mitochondrial dynamics
to facilitate the mitochondria-ER association required for signal
transduction. RLR activation actually induces degradation of one
MAVS isoform with the consequent disruption of a MAVS–Mfn1–
STING complex located at sites of ER-mitochondrial tethering, freeing
Mfn1 to orchestrate mitochondrial fusion. Fusion is required to
enhance further STING-MAVS interactions and the downstream
signaling propagation. Interestingly, we observed that expression of
vMIA, a CMV anti-apoptotic protein that promotes mitochondrial
fragmentation [60,61,64] (see above), hampers signaling downstream
from MAVS [65] suggesting a possible new immune modulation
strategy of the CMV required for its replication and pathogenesis
in vivo. It appears therefore that some viruses may also subvert innate
immunity by expressing proteins that induce mitochondrial morpho-
logical changes to impede signaling downstream of MAVS. Interest-
ingly, the viral pro-apoptotic factors HBx, viroporin 2B, OrfC and E1E4
described above also promote mitochondrial aggregation [80,82–84]
and in our hands, induction of mitochondrial aggregation leads to an
inhibition of MAVS-mediated signaling as well (unpublished
observations).7. Concluding remarks
The relation between mitochondria in innate immune responses
has been studied, until recently, mostly through the angle of host
cell death/survival. This is indeed a crucial point, as the fate of
infected cells critically impacts on the outcome of an infection at the
level of a tissue or the whole organism. Moreover, because
apoptosis and necrosis of infected cells result in dramatically
different inﬂammatory responses in the tissue microenvironment,
understanding how viruses regulate cell death pathways is of
crucial importance. The fact that so many cases of viral manipula-
tion of mitochondrial cell death pathways have been reported
reinforces the concept that the control of these cell death cascades
is essential for the physiopathology of a number of viruses. Yet, the
pathways linking detection of viral infection by PRRs to mitochon-
dria-mediated cell death remain poorly characterized. An interest-
ing challenge for the years will be to characterize in detail how
PRRs link viral detection to mitochondria-dependent cell death.
Finally, mitochondria appear to control much more than cell death/
survival following infection. This organelle seems to centralize a
number of critical innate immune responses, as illustrated by the
identiﬁcation of MAVS as a mitochondrial protein, and understand-
ing the reasons for such an interplay will undoubtedly represent an
interesting ﬁeld of investigation for the coming years.
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